Home | Sitemap | Search | Contact A- A A+
   
English
 
    Public Member Support us  
 
About IBCSG
Patients & Public
Breast Cancer Background
Breast Cancer Stages
IBCSG Clinical Trials
Open Trials
IBCSG 22-00
IBCSG 38-10
IBCSG 39-11
IBCSG 40-11 MA.32
IBCSG 42-12 SNAP
IBCSG 43-09 HOHO
Health Professionals
Tissue Bank / Translational Research
Home > Public > Patients & Public > IBCSG Clinical Trials > Open Trials > IBCSG 22-00

IBCSG 22-00 

Low-dose cytotoxics as "anti-angiogenesis treatment" following adjuvant induction chemotherapy for patients with ER-negative and PgR-negative breast cancer

DESIGN

Please click on the picture to see a larger version

Serum Substudy

Assessment of Vascular Endothelial Growth Factor (VEGF), Soluble Her2 Protein (NRP, Neu-Related Protein), and Vascular Cellular Adhesion Molecule-1 (VCAM-1) in serum samples.

Study Chair
Dr. Marco Colleoni - Milano, Italy

Statistician
Shari Gelber

Trial Coordinators
Holly Shaw, Renaye Hecker

Data Managers
Joie Celano, Sandra Lippert,


IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 836 6097
Email: ibcsg22@fstrf.org

Date of Activation
November 22, 2000

Targeted Accrual
900 patients

Substudies Serum Substudy


News

21.05.2013:
A few impressions from our audits

10.04.2013:
New publications are available

19.03.2013:
The next  IBCSG Annual Meeting will take place in Glasgow, Scotland on March 21nd and 22th, 2014.

All News

  
  Print
Disclaimer | Copyright